POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination

POMDOCTOR faces imminent Nasdaq delisting after sustained sub-$1.00 share price.

What the company is saying

POMDOCTOR LIMITED reports it received a Nasdaq staff determination letter on October 6, 2026, confirming non-compliance with the $1.00 minimum bid price rule after 30 consecutive business days below this threshold from August 24 to October 5, 2026. The company highlights that, due to a 1-for-18 reverse stock split on June 22, 2026, it is ineligible for the standard 180-day compliance period. POMDOCTOR states its securities are now subject to delisting and that trading suspension is scheduled for October 15, 2026, unless a timely appeal is filed. The company intends to request a hearing before the Nasdaq Hearings Panel by the October 13, 2026 deadline, which would temporarily stay any suspension or delisting action. The announcement emphasizes ongoing evaluation of alternatives to regain compliance but explicitly warns there is no assurance of a successful appeal or of regaining compliance. The tone is procedural and cautious, with no optimistic projections or minimization of risk.

What the data suggests

The facts confirm POMDOCTOR's closing bid price has been below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The company previously attempted to address compliance through a 1-for-18 reverse stock split on June 22, 2026, but this failed to sustain the share price above the minimum threshold. Because the reverse split occurred within the past year, Nasdaq rules deny the company any grace period to remedy the deficiency. As a result, the company's securities are now subject to delisting, with a trading suspension set for October 15, 2026 unless a hearing request is made by October 13, 2026. The company has not yet filed the appeal but intends to do so, which would temporarily halt delisting. No operational, financial, or turnaround data are disclosed; the release is strictly procedural and compliance-focused. The absence of any positive financial or business momentum, combined with the failed reverse split, signals a deteriorating position.

Analysis

The announcement is a factual compliance update regarding POMDOCTOR LIMITED's receipt of a Nasdaq staff determination letter for non-compliance with the minimum bid price requirement. The language is procedural and does not attempt to inflate the company's position or prospects. Forward-looking statements (such as the intent to appeal and evaluate alternatives) are presented with appropriate caution, including explicit disclaimers that there is no assurance of a successful outcome. There are no exaggerated claims of imminent recovery or overstatement of the likelihood of regaining compliance. The only capital action referenced is a previously completed reverse stock split, not a new or pending outlay. The data supports a neutral signal, as the disclosure is transparent about the company's compliance status and next steps, without promotional spin.

Risk flags

• ●Delisting risk is acute, as POMDOCTOR has already failed to meet the $1.00 minimum bid price for 30 consecutive business days and is ineligible for a compliance period due to a recent reverse split. This places the company on a fast track to removal from the Nasdaq Global Market.
• ●The company's only immediate recourse is to request a hearing before the Nasdaq Hearings Panel by October 13, 2026. Even if a hearing is granted, there is no assurance of a favorable outcome, and the company offers no concrete plan or evidence of how it will regain compliance.
• ●The failed reverse stock split on June 22, 2026, underscores the lack of effective options to boost share price, raising concerns about the company's underlying business health and ability to attract investor support or new capital.

Bottom line

POMDOCTOR LIMITED is at imminent risk of being delisted from Nasdaq after its share price remained below $1.00 for 30 consecutive business days, with no eligibility for a compliance period due to a recent 1-for-18 reverse split. The company has until October 13, 2026 to request a hearing, which would temporarily halt suspension and delisting, but there is no assurance of a successful appeal or a viable plan to restore compliance. No operational or financial turnaround evidence is presented, and the failed reverse split suggests structural challenges. Investors face the near-term risk of losing access to a major trading venue, which could further erode liquidity and value. The most important takeaway is that unless POMDOCTOR can rapidly and credibly address its compliance issues, its Nasdaq listing is likely to be lost.

Announcement summary

(NASDAQ:POM) POMDOCTOR LIMITED announced that it received a staff determination letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC on October 6, 2026. The letter notified the company that the closing bid price of its American depositary shares had been below $1.00 per share for 30 consecutive business days, from August 24, 2026 through October 5, 2026. As a result, the company is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). Normally, a Nasdaq-listed company would be given a 180-calendar-day period to regain compliance with the minimum bid price requirement. However, under Nasdaq Listing Rule 5810(c)(3)(A)(iv), the company is not eligible for any compliance period because it effected a 1-for-18 reverse stock split on June 22, 2026, within the prior one-year period. The staff determined that the company's securities are subject to delisting from The Nasdaq Global Market. Unless the company timely appeals the staff's determination to a Nasdaq Hearings Panel, its securities will be suspended from trading at the opening of business on October 15, 2026, and Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission to remove the company's securities from listing and registration on Nasdaq. The company intends to timely request a hearing before the panel to appeal the staff's determination and to present a plan to regain compliance with the minimum bid price requirement. The deadline for the company to request a hearing is October 13, 2026. A timely hearing request will stay the suspension of the company's securities and the filing of the Form 25-NSE pending the panel's decision. No suspension or delisting action will take effect while the appeal remains pending. The company is evaluating alternatives to regain compliance with Nasdaq's continued listing requirements. There can be no assurance that the panel will grant the company an extension of time to regain compliance, that the company will regain or maintain compliance with the minimum bid price requirement or any other Nasdaq continued listing requirement, or that the company's appeal will be successful.

Disagree with this article?